New Targeted Therapy Shows Promise for BRAF-Mutated Glioma
Early clinical trial data suggests a new drug may help patients with recurrent brain tumors.
Updated on Oct. 26, 2026 in Cancer
Live Poll
Do you trust that pharmaceutical companies prioritize patient safety over rapid development in new oncology treatments?
Nuvectis Pharma reported early clinical trial data showing NXP200, a potential treatment for BRAF V600-mutated gliomas, demonstrated tumor reduction in a study of 27 patients. This marks a new developmental step for patients with recurrent or progressive forms of these brain tumors.
Why it matters
The findings are notable because they offer a potential path for treating recurrent or progressive gliomas that harbor specific genetic mutations. As development continues, these preliminary results highlight the ongoing search for targeted therapies in patients with limited options.
In a Phase 1b study of 27 efficacy-evaluable patients, NXP200 showed an 85.2% disease control rate. Researchers observed high rates of deep tumor reduction, though these findings are preliminary and remain subject to further clinical confirmation.
The players
Nuvectis Pharma
A biopharmaceutical company based in Fort Lee, NJ, focused on the development of innovative precision medicine for oncology.
Center for Drug Evaluation
The regulatory body in China responsible for the review and approval of pharmaceutical drugs and clinical trial programs.
Haisco
A pharmaceutical company that originally developed NXP200 and subsequently licensed the rights to Nuvectis Pharma.
The details
The drug NXP200 was administered as a single-agent therapy to participants with recurrent or progressive BRAF V600-mutated gliomas. Efficacy was measured using RANO 2.0 criteria, which are standard protocols for assessing brain tumor treatment responses. Safety data indicated that 14.3% of evaluable patients experienced a Grade 3 or higher treatment-related adverse event.
Timeline
April 2026: NXP200 is selected for the Starlight Program in China.
May 4, 2026: Data cutoff date for the Phase 1b clinical trial.
June 2026: Nuvectis Pharma in-licenses worldwide rights to NXP200.
September 2026: NXP200 receives Breakthrough Therapy Designation in China.
October 26, 2026: Trial results are presented at the ESMO Congress in Madrid.
Health Landscape
The clinical investigation of NXP200 reflects the broader push toward precision oncology for brain tumors with specific molecular targets. The study uses the RANO 2.0 criteria as the benchmark for evaluating tumor response.
Patients currently navigating a diagnosis of recurrent glioma may discuss these early-stage developments with their oncology team to understand if future trials might be an option. As this drug is still in clinical development, it is not currently available for general clinical prescription.
The takeaway
Targeted therapies continue to emerge as a significant area of interest for patients with specific genetic mutations in brain tumors. Individuals interested in experimental treatments should consult with a neuro-oncologist about current clinical trial opportunities.
What happens next
Nuvectis Pharma intends to submit a U.S. Investigational New Drug (IND) application for NXP200 before the conclusion of 2026.
Further reading
Learn more about the latest research and clinical developments in Cancer.
Live Poll
Do you trust that pharmaceutical companies prioritize patient safety over rapid development in new oncology treatments?
